India’s dental products market remains fragmented, with distribution still dominated by traditional dealer networks. Vasa Denticity Ltd., through its Dentalkart platform, is trying to digitise this supply chain and build an online marketplace for dentists across the country.
After a difficult FY26, the company has entered FY27 with a sharper focus on execution. Management believes the challenges faced last year were operational rather than structural.
The stock continues to draw investor attention. As of March 2026, Ashish Kacholia held a 2.68 percent stake in the company, while Mukul Mahavir Agrawal owned 2.36 percent, according to the latest shareholding data.
With a market capitalisation of around Rs 650 crore, Vasa Denticity shares are trading near Rs 380. The stock trades at a P/E of 61, compared with the industry average of 35, and has gained more than 80 percent since its listing in June 2023.
Revenue grew despite exiting low-margin businesses
Management described FY26 as a year of both progress and setbacks.
The company exited around Rs 39 crore worth of low-margin trading activities to sharpen its focus on its core business, Dentalkart.
Despite the exit, revenue from operations rose to Rs 279 crore in FY26 from Rs 241 crore in FY25, registering growth of around 16 percent.
Profitability, however, came under pressure.
- Net profit fell to Rs 10 crore from Rs 17 crore a year earlier.
- The core business recorded growth of 33 percent.
- Around 70,000 new dentists were added during the year.
- The customer base expanded to 1.44 lakh dentists.
Management said many of the new customers came from tier-2 and tier-3 markets, where organised dental supply networks remain limited.
Another encouraging sign, according to the company, is that nearly two-thirds of newly acquired customers return within six months.
Stockouts hurt margins
The biggest setback during FY26 came from shortages in private-label products.
These products carry higher margins. Their unavailability weighed heavily on profitability.
Management identified stockouts as the primary reason behind the margin pressure.
Key numbers showed the impact:
- Gross margins declined from around 34 percent to 23.7 percent in Q4 FY26.
- Rupee depreciation increased import costs.
- EBITDA performance weakened during the year.
Management maintained that the underlying business remained healthy and said FY26 should not be viewed as a change in the company’s long-term prospects.
Supply chain mistakes took centre stage
One of the notable aspects of the earnings call was management’s willingness to accept responsibility.
The company acknowledged that supply chain errors led to shortages of private-label products. Replenishment took longer because these products required specialised packaging and regulatory approvals.
At one stage, shortages affected nearly 33 percent of private-label products.
That figure has now come down to 14.6 percent, though management said the acceptable range is 5-7 percent.
The company admitted that its push for inventory optimisation went too far and ended up affecting sales and customer wallet share.
Going forward, the focus will shift towards balancing:
- Inventory efficiency
- Product availability
- Growth
FY27 to revolve around execution
Management indicated that FY27 will be a year of strengthening the core business rather than pursuing multiple initiatives simultaneously.
Three immediate priorities have been identified:
- Better customer service
- Faster deliveries
- Wider product selection
The company plans to add categories that dentists currently buy from specialist suppliers outside the platform.
Management said the emphasis would be on improving execution rather than expanding aggressively.
Faster deliveries seen as an opportunity
Customer expectations have changed, influenced by the rise of quick commerce.
According to management, dentists increasingly expect rapid delivery of consumables needed for procedures.
Currently, around 60 percent of orders in tier-one cities are delivered the next day.
Over the long term, the company aims to create small fulfilment centres or dark stores across multiple cities.
Management estimated that nearly 25 small warehouses may eventually be required to achieve two-day delivery in tier-two cities.
Expansion plans, however, will come only after existing operations stabilise.
Building a wider dental ecosystem
Beyond the marketplace business, Vasa Denticity continues to explore adjacent opportunities.
Through subsidiary Smileworks, the company offers customised prosthetic products such as crowns and bridges.
Smileworks currently operates at an annual run rate of around Rs 4.8 crore. Management expects this to increase to Rs 10-12 crore during FY27.
The company is also experimenting with digital dentistry solutions, including:
- Diagnostics
- Scanning
- Treatment planning
- 3D printing
- Manufacturing processes
Management said these initiatives are intended to strengthen customer relationships and complement the core platform.
Growth ambitions remain
Management has adopted a more measured approach to guidance.
It acknowledged that earlier targets of reaching Rs 500-600 crore in revenue reflected the company’s limited experience as a listed entity.
Instead of aggressive short-term targets, the company now aims to double revenue every three to four years.
Although no formal guidance has been issued for FY27, management believes growth of around 30 percent remains achievable.
On margins, the company said FY26 was an exception rather than a “new normal”.
Its longer-term goals include:
- Improving EBITDA performance.
- Achieving mid-teen EBITDA margins over the next three to four years.
- Benefiting from operating leverage as revenue grows faster than manpower and warehousing costs.
Focus on cash flows
Investors have also been watching cash flow trends.
The company has reported negative operating cash flows in recent periods, largely because of investments in inventory.
Management reiterated that generating positive free cash flow per share remains a priority.
Inventory levels are expected to remain elevated in the near term, but the company aims to:
- Keep inventory below 120 days initially.
- Bring it below 100 days over the longer term.
Management also said there are no plans to raise fresh capital, adding that existing resources are sufficient to support growth.
Outlook
The tone of the FY26 earnings call marked a shift.
Instead of attributing challenges to external factors, management openly discussed execution mistakes and outlined corrective measures.
Vasa Denticity still operates in a large and underpenetrated market. Whether FY27 becomes a turning point will depend less on revenue growth and more on the company’s ability to restore margins, improve product availability and execute consistently.
TL;DR:
Vasa Denticity entered FY27 after margin pressure and supply chain disruptions hurt profitability in FY26. Management has shifted its focus to execution, customer experience and restoring private-label availability, while maintaining its long-term growth ambitions.
AI Summary:
- Revenue rose 16% to Rs 279 crore in FY26, while profit fell to Rs 10 crore.
- Stockouts in private-label products hurt margins and EBITDA.
- Management admitted supply chain mistakes and outlined corrective measures.
- FY27 priorities include customer service, faster deliveries and product expansion.
- Ashish Kacholia and Mukul Mahavir Agrawal remain shareholders.
